Cargando…
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
Immunotherapy is among the most rapidly evolving treatment strategies in oncology. The therapeutic potential of immune-checkpoint inhibitors is exemplified by the recent hail of Food and Drug Administration (FDA) approvals for their use in various malignancies. Continued efforts to enhance outcomes...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5956851/ https://www.ncbi.nlm.nih.gov/pubmed/29769148 http://dx.doi.org/10.1186/s40425-018-0349-3 |
_version_ | 1783323964776382464 |
---|---|
author | Chae, Young Kwang Arya, Ayush Iams, Wade Cruz, Marcelo R. Chandra, Sunandana Choi, Jaehyuk Giles, Francis |
author_facet | Chae, Young Kwang Arya, Ayush Iams, Wade Cruz, Marcelo R. Chandra, Sunandana Choi, Jaehyuk Giles, Francis |
author_sort | Chae, Young Kwang |
collection | PubMed |
description | Immunotherapy is among the most rapidly evolving treatment strategies in oncology. The therapeutic potential of immune-checkpoint inhibitors is exemplified by the recent hail of Food and Drug Administration (FDA) approvals for their use in various malignancies. Continued efforts to enhance outcomes with immunotherapy agents have led to the formulation of advanced treatment strategies. Recent evidence from pre-clinical studies evaluating immune-checkpoint inhibitors in various cancer cell-lines has suggested that combinatorial approaches may have superior survival outcomes compared to single-agent immunotherapy regimens. Preliminary trials assessing combination therapy with anti-PD-1/PD-L1 plus anti-CTLA-4 immune-checkpoint inhibitors have documented considerable advantages in survival indices over single-agent immunotherapy. The therapeutic potential of combinatorial approaches is highlighted by the recent FDA approval of nivolumab plus ipilimumab for patients with advanced melanoma. Presently, dual-immune checkpoint inhibition with anti-programmed death receptor-1/programmed cell death receptor- ligand-1 (anti-PD-1/PD-L1) plus anti-cytotoxic T lymphocyte associated antigen-4 (anti-CTLA-4) monoclonal antibodies (MoAbs) is being evaluated for a wide range of tumor histologies. Furthermore, several ongoing clinical trials are investigating combination checkpoint inhibition in association with traditional treatment modalities such as chemotherapy, surgery, and radiation. In this review, we summarize the current landscape of combination therapy with anti-PD-1/PD-L1 plus anti-CTLA-4 MoAbs for patients with melanoma and non-small cell lung cancer (NSCLC). We present a synopsis of the prospects for expanding the indications of dual immune-checkpoint inhibition therapy to a more diverse set of tumor histologies. |
format | Online Article Text |
id | pubmed-5956851 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-59568512018-05-24 Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC) Chae, Young Kwang Arya, Ayush Iams, Wade Cruz, Marcelo R. Chandra, Sunandana Choi, Jaehyuk Giles, Francis J Immunother Cancer Review Immunotherapy is among the most rapidly evolving treatment strategies in oncology. The therapeutic potential of immune-checkpoint inhibitors is exemplified by the recent hail of Food and Drug Administration (FDA) approvals for their use in various malignancies. Continued efforts to enhance outcomes with immunotherapy agents have led to the formulation of advanced treatment strategies. Recent evidence from pre-clinical studies evaluating immune-checkpoint inhibitors in various cancer cell-lines has suggested that combinatorial approaches may have superior survival outcomes compared to single-agent immunotherapy regimens. Preliminary trials assessing combination therapy with anti-PD-1/PD-L1 plus anti-CTLA-4 immune-checkpoint inhibitors have documented considerable advantages in survival indices over single-agent immunotherapy. The therapeutic potential of combinatorial approaches is highlighted by the recent FDA approval of nivolumab plus ipilimumab for patients with advanced melanoma. Presently, dual-immune checkpoint inhibition with anti-programmed death receptor-1/programmed cell death receptor- ligand-1 (anti-PD-1/PD-L1) plus anti-cytotoxic T lymphocyte associated antigen-4 (anti-CTLA-4) monoclonal antibodies (MoAbs) is being evaluated for a wide range of tumor histologies. Furthermore, several ongoing clinical trials are investigating combination checkpoint inhibition in association with traditional treatment modalities such as chemotherapy, surgery, and radiation. In this review, we summarize the current landscape of combination therapy with anti-PD-1/PD-L1 plus anti-CTLA-4 MoAbs for patients with melanoma and non-small cell lung cancer (NSCLC). We present a synopsis of the prospects for expanding the indications of dual immune-checkpoint inhibition therapy to a more diverse set of tumor histologies. BioMed Central 2018-05-16 /pmc/articles/PMC5956851/ /pubmed/29769148 http://dx.doi.org/10.1186/s40425-018-0349-3 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Chae, Young Kwang Arya, Ayush Iams, Wade Cruz, Marcelo R. Chandra, Sunandana Choi, Jaehyuk Giles, Francis Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC) |
title | Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC) |
title_full | Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC) |
title_fullStr | Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC) |
title_full_unstemmed | Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC) |
title_short | Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC) |
title_sort | current landscape and future of dual anti-ctla4 and pd-1/pd-l1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (nsclc) |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5956851/ https://www.ncbi.nlm.nih.gov/pubmed/29769148 http://dx.doi.org/10.1186/s40425-018-0349-3 |
work_keys_str_mv | AT chaeyoungkwang currentlandscapeandfutureofdualantictla4andpd1pdl1blockadeimmunotherapyincancerlessonslearnedfromclinicaltrialswithmelanomaandnonsmallcelllungcancernsclc AT aryaayush currentlandscapeandfutureofdualantictla4andpd1pdl1blockadeimmunotherapyincancerlessonslearnedfromclinicaltrialswithmelanomaandnonsmallcelllungcancernsclc AT iamswade currentlandscapeandfutureofdualantictla4andpd1pdl1blockadeimmunotherapyincancerlessonslearnedfromclinicaltrialswithmelanomaandnonsmallcelllungcancernsclc AT cruzmarcelor currentlandscapeandfutureofdualantictla4andpd1pdl1blockadeimmunotherapyincancerlessonslearnedfromclinicaltrialswithmelanomaandnonsmallcelllungcancernsclc AT chandrasunandana currentlandscapeandfutureofdualantictla4andpd1pdl1blockadeimmunotherapyincancerlessonslearnedfromclinicaltrialswithmelanomaandnonsmallcelllungcancernsclc AT choijaehyuk currentlandscapeandfutureofdualantictla4andpd1pdl1blockadeimmunotherapyincancerlessonslearnedfromclinicaltrialswithmelanomaandnonsmallcelllungcancernsclc AT gilesfrancis currentlandscapeandfutureofdualantictla4andpd1pdl1blockadeimmunotherapyincancerlessonslearnedfromclinicaltrialswithmelanomaandnonsmallcelllungcancernsclc |